CYTK: Cytokinetics Inc. Company Profile & Statistics

Cytokinetics Inc. Profile

About

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.

Info & Links

CEO

Robert I. Blum

Headquarters

350 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

673

Cytokinetics Inc. Statistics

Valuation Measures

Market Capitalization²

7.75B

Enterprise Value

8.78B

Enterprise Value/EBITDA(ttm)

-14.58

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

83.97

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-753.88%

Profit Margin(ttm)

-6816.81%

Return on Equity(ttm)

Return on Invested Capital(ttm)

-179.82%

Return on Assets(ttm)

-49.62%

Income Statement

Revenue(ttm)

88.04M

Revenue Per Share(ttm)

0.71

Gross Profit(ttm)

88.04M

EBITDA(ttm)³

-602.13M

Net Income Available to Common(ttm)

-784.95M

Diluted EPS(ttm)

-6.53

Share Statistics

Beta (5Y Monthly)

0.56

52-Week Change

41.17%

S&P 500 52-Week Change

14.99%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

123.16M

Dividend Yield

0.00%

Float⁴

119.84M

% Held by Insiders

2.70%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

882.22M

Total Cash Per Share(mrq)

7.16

Total Debt(mrq)

1.16B

Total Debt/Equity(mrq)

-175.43%

Current Ratio(mrq)

4.53%

Quick Ratio(mrq)

4.53%

Book Value Per Share(mrq)

-5.37

Cash Flow

Operating Cash Flow Per Share(ytd)

-4.25

Free Cash Flow(ytd)

-534.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CYTK

Cytokinetics Inc.